Dems Come Out Swinging During Azar Senate HELP Committee Hearing
During his first Senate confirmation hearing, top Democrats attacked Trump HHS secretary nominee Alex Azar for his ties to the pharmaceutical industry and support of right-wing ideology espoused by the White House.
You may also be interested in...
US HHS Secretary Nominee Alex Azar was approved by the Senate Finance Committee on Jan. 17, sending his nomination to the full Senate for consideration. The former pharmaceutical company executive supports approval of additional telehealth reimbursements and, at a recent confirmation hearing, he discussed more access to durable medical equipment for patients in competitive bidding program areas.
During the first step of the confirmation process, HHS Secretary nominee Alex Azar did a good job of framing his industry background as useful experience for tackling drug prices. But wouldn’t it be nice if everyone agreed that 10 years as Lilly was something to be proud of?
In an exclusive sit-down with Scott Whitaker, the head of the largest medical device lobby group tells Medtech Insight why pharmaceutical companies should be concerned about Trump HHS Secretary nominee Alex Azar, his frustration with Congress' device tax repeal efforts, the growing likelihood of another temporary device tax moratorium and more. Listen to the podcast.